Скачать с ютуб MERAIODE Trial: Thyroid Cancer Breakthrough (BRAFV600E) w/ Dr. Leboulleux в хорошем качестве

MERAIODE Trial: Thyroid Cancer Breakthrough (BRAFV600E) w/ Dr. Leboulleux

We are honored to have Dr. Sophie Leboulleux present "MERAIODE: A Redifferentiation Phase II Trial with Trametinib & Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients with a BRAFV600E Mutation." Dr. Jim Fagin joins as the featured expert discussant. 0:00 Webinar 2:46 Dr. Leboulleux Presents Dr. Leboulleux presents her phase II redifferentiation study, giving background on the topic and introducing the study's methodology. 8:55 Dr. Leboulleux Shares the Results 24 patients with papillary thyroid cancer were enrolled, with a median age of 67 and with the majority of patients being women. 22:00 Dr. Leboulleux Discusses Limitations & Conclusions They found that for patients with BRAF p.V600E mutated differentiated thyroid cancer, dabrafenib and trametinib were effective for restoring iodine uptake in 95% of patients, with long-lasting tumor response rates. 24:27 Dr. Fagin Presents Dr. Fagin provides additional context regarding redifferentiation therapies and the current state of our knowledge on the topic. He begins by answering the question "who responds and who doesn't to conventional radioiodine therapy?" 30:51 Exceptional Responders to RAI Therapy 8 patients were studied from Memorial Sloan Kettering who had a RECIST v1.1 response to RAI therapy based on measurements of distant metastatic lesions. 41:28 Rationale for Redifferentiation Therapy Dr. Fagin discusses the rationale for redifferentiation therapy and who qualifies for this experimental treatment. 46:41 Discussion with Q&A ** Check out our other programs! ** The THANC Guide https://thancguide.org/ TIRO: Thyroid Int'l Recommendations Online https://tiro.expert/ ** Follow us on Twitter! ** @thancfoundation - https://shorturl.at/puwS0 THANC on FB - https://shorturl.at/svNY4